Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Consumer outlook on UK economy falls to two-year low - 2Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
- 3Current Chateaus: Advancement and Style
- 4The many ways that baking is winter therapy. With a delicious ending
- 5Honda’s Biggest Flex Isn’t Its Superbikes, It’s Selling 500K Bikes In One Month
- What is the Insurrection Act? Can Trump really use the military to 'put an end' to Minneapolis ICE protests?
- Christmas 2025 skywatching guide: What you can see in the night sky on Dec. 25
- Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know
- Vote In favor of Your Favored IT Administration
- San Francisco mayor says city in talks to bring pandas back to zoo ahead of trip to Asia
- FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- Vote In favor of Your Favored Kind Of Vegetable
- 'It's doing badly': Fears grow for whale stuck off Germany's coast
- Public Parks in the USA
